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Abstract
Background: Community-Associated Methicillin Resistant Staphylococcus aureus (CA-MRSA) has traditionally been
related to skin and soft tissue infections in healthy young patients. However, it has now emerged as responsible
for severe infections worldwide, for which vancomycin is one of the mainstays of treatment. Infective endocarditis
(IE) due to CA-MRSA with heterogeneous vancomycin-intermediate susceptibility-(h-VISA) has been recently
reported, associated to an epidemic USA 300 CA-MRSA clone.
Case Presentation: We describe the occurrence of h-VISA phenotype in a case of IE caused by a strain belonging
to an epidemic CA-MRSA clone, distinct from USA300, for the first time in Argentina. The isolate h-VISA (SaB2) was
recovered from a patient with persistent bacteraemia after a 7-day therapy with vancomycin, which evolved to
fatal case of IE complicated with brain abscesses. The initial isolate-(SaB1) was fully vancomycin susceptible (VSSA).
Although MRSA SaB2 was vancomycin susceptible (≤2 μg/ml) by MIC (agar and broth dilution, E-test and VITEK 2),
a slight increase of MIC values between SaB1 and SaB2 isolates was detected by the four MIC methods, particularly
for teicoplanin. Moreover, Sab2 was classified as h-VISA by three different screening methods [MHA5T-screening
agar, Macromethod-E-test-(MET) and by GRD E-test] and confirmed by population analysis profile-(PAP). In addition,
a significant increase in cell-wall thickness was revealed for SaB2 by electron microscopy. Molecular typing showed
that both strains, SaB1 and SaB2, belonged to ST5 lineage, carried SCCmecIV, lacked Panton-Valentine leukocidin-
(PVL) genes and had indistinguishable PFGE patterns (subtype I2), thereby confirming their isogenic nature. In
addition, they were clonally related to the epidemic CA-MRSA clone (pulsotype I) detected in our country.
Conclusions: This report demonstrates the ability of this epidemic CA-MRSA clone, disseminated in some regions
of Argentina, to produce severe and rapidly fatal infections such as IE, in addition to its ability to acquire low-level
vancomycin resistance; for these reasons, it constitutes a new challenge for the Healthcare System of this country.
* Correspondence: csola@fcq.unc.edu.ar
1Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-
CONICET); Departamento de Bioquímica Clínica; Facultad de Ciencias
Químicas; Universidad Nacional de Córdoba; Córdoba, Argentina
Full list of author information is available at the end of the article
Sola et al. Annals of Clinical Microbiology and Antimicrobials 2011, 10:15
http://www.ann-clinmicrob.com/content/10/1/15
© 2011 Sola et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Community-associated methicillin resistant Staphylococ-
cus aureus-(CA-MRSA) has rapidly become the main
cause of S. aureus infections worldwide since 1993.
These non-multiresistant strains frequently harbor sta-
phylococcal-cassette-chromosome-(SCCmec) types IV or
V and Panton-Valentine leukocidin-(PVL) genes. The
worldwide increase of CA-MRSA infections is due to
the dissemination of some epidemic CA-MRSA clones
harboring pvl genes (PVL
+), with a specific geographical
pattern, these are frequently designated by their multilo-
cus sequence type (MLST) or by their pulsed field gel
electrophoresis (PFGE) pattern (ST1, ST8-USA300,
ST30, ST59, ST93 and ST80) [1-4].
Although CA-MRSA was initially related to skin and
soft tissue infections, it has now emerged as a cause of
severe infections worldwide [1]. Vancomycin has tradi-
tionally been the mainstay of therapy for these serious
MRSA infections, thereby the emergence of resistance
to this agent is of great concern [5,6]. Heterogeneous
vancomycin intermediate S. aureus (h-VISA) is an iso-
late of S. aureus with a vancomycin MIC within the sus-
ceptible range (≤2 μg/ml) when tested by routine
methods, containing subpopulations of cells (typically at
af r e q u e n c yo f≤10
-5 to 10
-6) with intermediate resis-
tance to vancomycin (VISA: MIC 4-8 μg/ml) [5]. This
type of resistance is associated with a thickened cell-wall
that prevents vancomycin action over its target within
the cytoplasmic membrane. The exact mechanisms lead-
ing to this thickening have not been determined yet [5].
Lately, cases of infective endocarditis (IE) caused by
CA-MRSA, mainly associated with the USA300 geno-
type have been reported [7-9]. More recently, phenotype
h-VISA related to USA300 CA-MRSA clone has also
been described [3,10-12]. On the other hand, the emer-
gence of a ST5-IV clone PVL
+ among CA-MRSA strains
in Argentina was detected in 2005 [4,13].
We report the occurrence of h-VISA phenotype in a
case of IE caused by this epidemic CA-MRSA clone for
the first time in this country.
Case Presentation
On April 4, 2009, a 73-year-old female with sudden
weakness in the extremities was admitted at Institution
A. On admission, she was afebrile and the head com-
puted tomography (CT) was normal. She had underlying
chronic rheumatic valve disease and chronic atrial fibril-
lation. She had no previous exposure to healthcare per-
sonnel or hospital environment during the previous
year. Forty-eight hours after admission, the patient
developed fever (38°C) and depression of the sensorium;
hence, she was transferred to the Intensive Care Unit
(ICU). Abdominal CT scan and echo-Doppler of the
carotid vessels were normal.
MRSA grew in three blood cultures (SaB1-strain) and
one urine culture (SaU-strain) taken upon admission in
the ICU on April 7. A transthoracic echocardiography
(TE) showed a filamentous mobile image attached to the
ventricular side of the aortic valve, which resembled
vegetations, suggesting a MRSA infection that met
Duke’s criteria for IE [14]. These isolates were susceptible
to ciprofloxacin, gentamicin, rifampicin, tetracycline, tri-
methoprim-sulfamethoxazole-(TMP-SMX) and linezolid
by disk diffusion and broth microdilution methods (see
Additional file 1, Table S1) [15] and resistant to erythro-
mycin and clindamycin (inducible resistance, D-test posi-
tive) [15]. In addition, vancomycin MIC was 1 μg/ml by
broth dilution method [15]. Vancomycin treatment (15
mg/kg every 12 h) was initiated on April 7 and the
patient was transferred to “Hospital-Militar-Regional-
Córdoba-(HMRC)” for further evaluation on April 8.
Antibiotic levels in blood were not available, so the same
dose of vancomycin was continued; which is recom-
mended to maintain the level of vancomycin in the valley
of 10-15 μg/ml. The patient had fever of 39.2°C accompa-
nied by Janeway’s lesions on the hands. On April 9, valve
replacement was postponed because of a worsening of
the neurological symptoms and hypotension. Roth’s spots
were detected. The brain CT revealed no changes. On
April 12, the patient presented hemodynamic and neuro-
logical improvement; a transoesophageal echocardiogra-
phy (TEE) showed a highly mobile vegetation on the
aortic valve (Figure 1). On April 14, the patient had
altered mental status and persistent fever. Brain magnetic
resonance-image-MRI with gadolinium showed multiple
abscesses (Additional file 2, Figure S1). On April 15,
since the patient worsened, valve replacement was post-
poned again; treatment failure was suspected and tri-
methoprim/sulfamethoxazole (15 mg/kg/day) was added
Figure 1 Transesophageal echocardiography of a patient with
infective endocarditis caused by CA-MRSA with phenotype h-
VISA, Argentina. Left: On April 12, the highly mobile vegetation on
the aortic valve (AV) of 20 × 41 mm (white arrow). Right: On April
24, slight decrease in the aortic valve (AV) vegetation (white arrow)
and a new vegetation on the mitral valve (MV) (10 × 4.6 mm) of
low motility (white arrow).
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Page 2 of 6to vancomycin. On April 17, the patient remained febrile,
three new samples for blood culture taken on April 14
revealed MRSA (strain SaB2) with the same susceptibility
to antibiotics, except for vancomycin, which reached a
MIC of 2 μg/ml (broth dilution [15]. On April 20, the
patient was afebrile. Three additional sets of blood cul-
tures were drawn providing negative results. On April 24,
a control TEE (Figure 1) showed a slight decrease of the
size of the aortic valve vegetation and a new vegetation
on the mitral valve. The patient had evident deterioration
of mental and physical status and died on April 25 before
surgical intervention.
The emergence of h-VISA phenotype in a CA-MRSA
was suspected based on the rapid and fatal outcome of
the patient, the facts that the IE was caused by MRSA
without multiresistance to antibiotics, failure of vanco-
mycin therapy (defined as persistent fever and bacterae-
mia longer than 7 days after onset of therapy) and
increase of vancomycin MICs values (1 to 2 μg/ml)
within therapy. This prompted us to further analyze
these strains. The blood (SaB1 and SaB2) and urine
(SaU) MRSA isolates were sent to the CIBICI ("Centro
de Investigaciones en Bioquimica Clinica e Inmunolo-
gia"; UNC-CONICET); for additional analysis including
molecular and genetic characterization.
Phenotypic and genotypic characterizations of MRSA
The slight increase of MIC values between the initial
(SaU and SaB1) and subsequent (SaB2) isolates was
detected by four MICs methods [15], particularly for tei-
coplanin (Table 1). The isolates were also sent to the
“Instituto-Nacional-de-Enfermedades-Infecciosas Dr.
Carlos G. Malbrán” to independently confirm the MIC
results for vancomycin and teicoplanin. Moreover, SaB2
was classified as h-VISA by three screening methods,
MHA5T-screening agar, Macromethod-E-test-(MET)
and GRD E-test (Table 1) [5]. Although MRSA SaB2
was vancomycin susceptible by MIC, it grew in BHI
agar containing 4.0 μg/mL of vancomycin at a frequency
of 1.6 × 10
-6 on population analysis profile-(PAP)
[16,17], which is consistent with h-VISA (Additional file
3, Figure S2). Vancomycin MICs by broth-dilution; agar-
dilution and E-test were determined for these derivatives
and all were between 4 and 8 μg/ml. Neither MRSA
SaB1 isolate nor S. aureus ATCC 29213 grew in BHI
agar with 4 μg/ml. In addition, electron microscopy
examination [5,18] of SaB2 and one derivative VISA
obtained on PAP, revealed that the cell-wall of both iso-
lates was thicker (p< 0.001) than the parent strain SaB1
(Figure 2), a feature observed for most strains with
VISA and h-VISA phenotypes. Moreover, the h-VISA
phenotype found in strain SaB2 was unstable, since van-
comycin MICs in all isolates with MICs ≥2 μg/ml
reverted to MICs ≤1 μg/ml (susceptible phenotype-
VSSA) after multiple subcultures in absence of vanco-
mycin. Importantly, the detection by PCR [11] of vanA
and vanB genes was negative.
The clinical isolates (SaU, SaB1 and SaB2) and the deri-
vatives obtained on PAP were analyzed by PFGE,
MLST, SCCmec and spa typing, in addition to the
detection of virulence genes by PCR, as previously
reported [4]. Molecular typing revealed that all these
isolates had indistinguishable pulsotypes (subtype I2)
(Additional file 4, Figure S3) and were characterized as
ST5, agr-2, spa-t045, associated to SCCmec-IV. The egc
(seg, sei, sem, sen and seo) and lukED genes were
detected among all the virulence genes analyzed by PCR
in these three isolates. They do not harbor pvl and sea
genes. The results confirmed the isogenic nature of
these isolates and their clonality with the CA-MRSA
clone (pulsotype I) detected in our country (Additional
file 4, Figure S3).
Discussion
Currently, PVL negative CA-MRSA strains belonging to
some successful PVL positive CA-MRSA clones (ST1,
Table 1 Susceptibility of urine-(SaU) isolate and blood isolates obtained before (SaB1) and during (SaB2) vancomycin
therapy
Isolates Broth dilution
μg/ml
Agar dilution
μg/ml
E-test
μg/ml
VITEK 2
μg/ml
MET
μg/ml
GRD strip
μg/ml
MHA5T
VAN TEIC VAN TEIC VAN TEIC VAN TEIC VAN TEIC VAN
24 h/48 h
TEIC
24 h/48 h
TEIC
SaU 1 1 1 1 1 1 1 ≤ 05 4 8 1/1 2/2 -
SaB1 1 (1)* 1 1 1 1 (1.5)* 1 (1)* 1 ≤ 05 4 8 1/1 2/2 -
SaB2 2 (2)* 4 2 4 2 (2)* 2 (1.5)* 2 4 12 12 4/4 12/16 +
MIC: Minimum inhibitory concentration, VAN: vancomycin, TEIC: teicoplanin, MET: Macromethod E-test, 200 μl of inoculum at 2 McFarland standard suspensions
onto BHI Agar, positive result: VAN MIC of ≥8 and TEIC MIC of ≥8 μg/ml or TEIC MIC of ≥12 μg/ml; GRD strip, Etest Glycopeptide-resistance (AB bioMérieux)
detection strip were used as described by the manufacture:GRD positive (GISA o h-GISA): VAN o TEIC ≥ 8 μg/ml; MHA5T screening, Mueller Hinton Agar with 5
μg/ml of TEIC, 10 μl of inoculum at 0.5 McFarland-standard direct-colony suspensions. Any growth was considered positive. All screening methods were read at
24 and 48 h and incubated at 35°C. (MIC)*: MIC results from the Instituto Nacional de Enfermedades Infecciosas Dr. Carlos G. Malbran. The strains h-VISA-Mu3
and VISA-Mu50 and the vancomycin-susceptible S. aureus strain ATCC 29213 were tested for all methods in parallel, as positive and negative controls,
respectively.
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detected, particularly in Europe and Asian-Pacific coun-
tries [1,19-21]. In the case of the CA-MRSA IE reported
here, the molecular typing revealed that although these
strains share the same successful lineage ST5 with CA-
MRSA (ST5-IV) and -HA-MRSA (ST5-I) epidemic
clones disseminated in this country, their PFGE pattern
is closer to that of the CA-MRSA clone (one band of
difference with I1, additional Figure 3). Moreover, this
isolate carries the SCCmec type IV and is non-multire-
sistant to antibiotics. Consequently, results identify a
PVL-negative variant (PVL
-)o ft h eS T 5 - I VC A - M R S A
epidemic clone detected in Argentina. Importantly, this
clone belongs to lineage ST5, which has been demon-
strated [5] to develop the VISA phenotype, but so far
associated to HA-MRSA clones (ST5-II), unlike our
case. These characteristics could confer another selective
advantage for its dissemination in Argentina and neigh-
boring countries.
Presently, strains of MRSA demonstrating the h-VISA
or VISA phenotype have been reported in many coun-
tries worldwide, but in Latin America, cases with these
phenotypes have been reported only in Northern coun-
tries and Brazil [3,5]. Furthermore, only one case of CA-
MRSA infective endocarditis from Brazil has been
reported for South America, but not associated to a
h-VISA strain like our case[22]. In Argentina, the h-
VISA phenotype in MRSA strains was detected for the
first time in 2009. Thus, our case is the first one asso-
ciated to persistent bacteremia under vancomycin ther-
apy. Three additional cases were independently detected
in Buenos Aires during the same year (presented at
“Congreso Argentino de Infectología -SADI 2010” and
at “XX-Congreso Latinoamericano de Microbiología;
Montevideo-2010”, unpublished data). Even in infections
with “high-risk” of presence of h-VISA phenotype, such
as IE, the prevalence of h-VISA varies significantly and
is potentially associated with non-clinical factors, such
as geographic location [14]. Hence, the knowledge about
general and molecular epidemiology of h-VISA pheno-
type in different countries is essential for effective pre-
vention and therapy.
On the other hand, the cases of CA-MRSA IE subse-
quently published occurred in healthy young patients
without classical risk factors for IE [7]. This report,
along with another case of CA-MRSA IE recently
described in Italy, [8] support the importance of consid-
ering this emergent pathogen as a potential cause of IE
for subjects with risk for IE (elderly patients, pre-exist-
ing heart diseases, etc). Hence, our report adds new
information about CA-MRSA associated to h-VISA phe-
notype epidemiology, which is a matter of great interest
in clinical microbiology and molecular epidemiology
worldwide.
In addition, our case highlights the difficulties of
laboratory detection of h-VISA-phenotype, particularly
when it is unstable and arises from a fully susceptible
VSSA isolate (vancomycin MIC ≤1 μg/ml) under treat-
ment with vancomycin. Furthermore, upon detection,
t h ec h o i c eo fa p p r o p r i a t et h e rapy still remains difficult
[5,6]. Daptomycin, vancomycin, teicoplanin, linezolid,
TMP-SMX, and quinupristin-dalfopristin are potential
options for the treatment of MRSA bacteraemia
[6,23,24]. The treatment of our patient raises several
questions and reflects the lack of evidence-based data to
guide the choice of therapy for CA-MRSA IE caused for
isolates expressing h-VISA phenotype with vancomycin
MICs of 2 μg/ml [5,6]. Our patient received vancomycin
as first line therapy at recommended doses [6,23]. How-
ever, due to the clinical worsening of the patient, which
prevented the valvular surgery, in addition to the pre-
sence of brain abscesses, we decided to add TMP-SMX
to vancomycin, even before knowing that vancomycin
MIC value had risen to 2 μg/ml. TMP-SMX has bacteri-
cidal activity in-vitro and it may be considered to be an
alternative therapy to vancomycin for MRSA infection
[6,24-26]. In our patient, although the last set of blood
cultures may have been negative for different reasons,
including changes in renal function, TMP-SMX appar-
ently contributed to bacteraemia clearance. Only few
Figure 2 Transmission electron microscopy of initial isolate
(SaB1)-VSSA vs. after persistent bacteremia isolate (SaB2)-h-
VISA. Comparison of the cell thickness among the pair of strains
(SaB2 vs SaB1) and one derivative VISA (CIM 4 μg/ml) obtained on
PAP (PAPd4). Quality control strains included S. aureus ATCC 29213
and Mu50, control, negative and positive for VISA, respectively.
Magnification: × 60,000. Values given under each image are mean ±
SD of the cell wall thickness in nanometers. Student’s t test
demonstrated that this augment in cell wall thickness was
statistically significant (p< 0.001).
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treated with TMP-SMX in addition to vancomycin, late
in the course of bacteriemia, but these are not enough
to assess the clinical outcome [27]. Daptomycin was not
considered due to the potential risks in patients with
bacteremia, in which a deep focus of infection has not
been surgically debrided, as well as for patients with
left-side endocarditis [28], two characteristics seen in
our patient.
O n eo ft h el i m i t a t i o n so ft h i sr e p o r ti st h ea b s e n c eo f
measurements of vancomycin serum concentrations due
to technical problems of the clinical laboratory at that
time. Hence, although we think that, considering the
clinical characteristics of the patient, the dose of vanco-
mycin that she received should have been enough to
reach or even exceed the recommended therapeutic
level [6,27], we cannot demonstrate it. In summary, the
failure of vancomycin to eradicate this CA-MRSA strain
was likely due to the presence of several important fac-
tors: I) high-bacterial-load during infection, combined
with the impossibility to perform the cardiac surgery, II)
slow bactericidal mechanism of vancomycin, III) the
ability of this CA-MRSA clone to develop h-VISA phe-
notype and IV) the virulence of the CA-MRSA strain,
possibly related to the metastatic complications and
rapid progression [5,23].
Conclusions
This report demonstrates the ability of this epidemic
CA-MRSA clone, disseminated in some regions of
Argentina, to cause severe and rapidly fatal infections
such as infective endocarditis, in addition to its capacity
to acquire low-level vancomycin resistance; for this rea-
son, it has become a challenge for the healthcare system
in our country. Therefore, systematic surveillance along
to molecular epidemiology and quick diffusion of the
results in each region are crucial for proper manage-
ment of these infections.
Consent
Written informed consent was obtained from the
patient’s son for publication of this case report and any
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal
Additional material
Additional file 1: Table S1: Antimicrobial susceptibility profile of
urine-(SaU) isolate and blood isolates obtained before-(SaB1) and
during-(SaB2) vancomycin therapy. CLSI: Clinical and Laboratory
Standards Institute, MIC: Minimum inhibitory concentration by broth
microdilution (VITEK 2) per CLSI guideline, R*: Inducible Clindamycin
Resistance.
Additional file 2: Figure S1: MRI (two slices) showing brain
abscesses (white arrows) in a patient with CA-MRSA infective
endocarditis. MRI: magnetic resonance image (with gadolinium).
Additional file 3: Figure S2: Vancomycin population analysis profiles
of initial isolate-(SaB1)-VSSA and after persistent bacteremia
isolate-(SaB2)-h-VISA, despite vancomycin therapy SaB1: initial
isolate, prior to vancomycin therapy. Also, hVISA and VISA reference
strain Mu3 and Mu50 respectively and VSSA strain ATCC 29213. Briefly,
PAP was performed by serial dilution of overnight BHIB culture and
inoculation of BHI agar containing 0 to 8 μg/ml of vancomycin. Colonies
were counted after incubation for 48 h in air at 35°C and plotted on a
graph of the number of CFU/ml versus vancomycin concentration.
Additional file 4: Figure S3: PFGE-Analysis confirmed the clonality
of the clinical isolates (SaU-SaB1-SaB2), belonging to CA-MRSA
clone ST5-IV-PVL+. Sma I restriction patterns were indistinguishable for
SaU (urine isolate), SaB1 (initial blood isolate) and SaB2 (later blood
isolate), 1-5: five derivatives from SaB2 in PAPs (CIM ≥4 μg/ml), PFGE
DNA pattern of representative of major clonal types belonging to ST5
lineage, both CA and HA-MRSA from Argentina, to be compared with
subtype I2 CA-MRSA (ST5-IV-PVL¯): CA-MRSA I1 (ST5-IV-PVL
+), HA-MRSA
A1-Cordobes/Chilean clone (ST5-I) and HA-MRSA C1 Pediatric clone
(ST100-IV). I6 refers to the PFGE pattern of a MSSA isolate from Córdoba,
which shows a unique band difference with the I2 subtype, isolated from
our patient. NC: NCTC 8325 control strain L: DNA molecular size markers
in kb (lambda DNA ladder, Promega).
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